Company Overview and News
By far the most exciting real-time revolution unfolding in Biotechnology is CRISPR gene editing. And the past few months have provided plenty of excitement for Biotech investors as the three public companies who are pure-play manifestations of the technology have made some dramatic moves -- on good news and bad.
NTLA EDIT IP GILD INPAP CRSP
Investors focused on the Medical space have likely heard of Editas Medicine (EDIT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Tetraphase Pharma (TTPH) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; they also have a Qualified Infectious Disease Product (‘QIDP) for the drug candidate.
NTLA MKGAF OPK RCUS CORV ENL AQXP CUR EDIT ALXN AGN ADXS PFNX GTBP AMGN VTGN CRSP MDWD LLY SNY VICL LIVN MKGAY LIVN ENDP
CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a panel and host investor meetings at the JMP Securities Life Sciences Conference in New York on Wednesday, June 20, 2018. Details of the panel are as follows:
We recently documented the potential of Genome Editing technology to revolutionize the treatment of many serious diseases and three companies who are positioned to use a specific method of gene therapy called CIRSPR Cas9 to repair genetic diseases - CRISPR Therapeutics (CRSP - Free Report) , Intellia Therapeutics (NTLA - Free Report) and Editas Medicine (EDIT - Free Report) .
NTLA VRTX ELY EDIT CRSP
7h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
8h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to EDIT / Editas Medicine, Inc. on message board site Silicon Investor.
as of ET